alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
##### 



Exhibit 31(a) REPUBLIC BANCORP INC.
Certification of the Principal Executive Officer
Pursuant to 15 U.S.C. 78m(a) or 78o(d)
(Section 302 of the Sarbanes-Oxley Act of 2002) I, Dana M. Cluckey, certify that:  1.
    
    I have reviewed this report on Form 10-Q of Republic Bancorp Inc;2.
    
    Based on my knowledge, this report does not contain any untrue
statement of a material fact or omit to state a material fact necessary
to make the statements made, in light of the circumstances under which
such statements were made, not misleading with respect to the period
covered by this report;3.
    
    Based on my knowledge, the financial statements, and other financial
information included in this report, fairly present in all material
respects the financial condition, results of operations and cash flows
of the registrant as of, and for, the periods presented in this report;4.
    
    The registrants other certifying officer and I are responsible for
establishing and maintaining disclosure controls and procedures (as
defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the
registrant and we have:  a)
    
    designed such disclosure controls and procedures, or caused
such disclosure controls and procedures to be designed under our
supervision, to ensure that material information relating to the
registrant, including its consolidated subsidiaries, is made known
to us by others within those entities, particularly during the
period in which this report is being prepared;b)
    
    evaluated the effectiveness of the registrants disclosure
controls and procedures and presented in this report our conclusions
about the effectiveness of the disclosure controls and procedures,
as of the end of the period covered by this report based on such
evaluation; andc)
    
    disclosed in this report any change in the registrants
internal control over financial reporting that occurred during the
registrants most recent fiscal quarter (the registrants fourth
fiscal quarter in the case of an annual report) that has materially
affected, or is reasonably likely to materially affect, the
registrants internal control over financial reporting; and  5.
    
    The registrants other certifying officer and I have disclosed, based
on our most recent evaluation of internal control over financial
reporting, to the registrants auditors and the audit committee of the
registrants board of directors (or persons performing the equivalent
functions):  a)
    
    all significant deficiencies and material weaknesses in the
design or operation of internal controls over financial reporting
which are reasonably likely to adversely affect the registrants
ability to record, process, summarize and report financial
information; andb)
    
    any fraud, whether or not material, that involves management
or other employees who have a significant role in the registrants
internal control over financial reporting. Date: May 7, 2004
    
    /s/ Dana M. CluckeyDana M. CluckeyPresident and Chief Executive Officer
§ 349.12 Ophthalmic demulcents. The active ingredients of the product consist of any of the following, within the established concentrations for each ingredient: ( a ) Cellulose derivatives: ( 1 ) Carboxymethylcellulose sodium, 0.2 to 2.5 percent.
( 2 ) Hydroxyethyl cellulose, 0.2 to 2.5 percent.
( 3 ) Hypromellose, 0.2 to 2.5 percent.
( 4 ) Methylcellulose, 0.2 to 2.5 percent.
( b ) Dextran 70, 0.1 percent when used with another polymeric demulcent agent in this section.
( c ) Gelatin, 0.01 percent.
( d ) Polyols, liquid: ( 1 ) Glycerin, 0.2 to 1 percent.
( 2 ) Polyethylene glycol 300, 0.2 to 1 percent.
( 3 ) Polyethylene glycol 400, 0.2 to 1 percent.
( 4 ) Polysorbate 80, 0.2 to 1 percent.
( 5 ) Propylene glycol, 0.2 to 1 percent.
( e ) Polyvinyl alcohol, 0.1 to 4 percent.
( f ) Povidone, 0.1 to 2 percent.
[53 FR 7090, Mar. 4, 1988, as amended at 68 FR 32982, June 3, 2003]
§ 514.15 Untrue statements in applications. Among the reasons why an application for a new animal drug or animal feed bearing or containing a new animal drug may contain an untrue statement of a material fact are: ( a ) Differences in: ( 1 ) Conditions of use prescribed, recommended, or suggested by the applicant for the product from the conditions of such use stated in the application;
( 2 ) Articles used as components of the product from those listed in the application;
( 3 ) Composition of the product from that stated in the application;
( 4 ) Methods used in or the facilities and controls used for the manufacture, processing, or packing of the product from such methods, facilities, and controls described in the application;
( 5 ) Labeling from the specimens contained in the application; or
( b ) The unexplained omission in whole or in part from an application or from an amendment or supplement to an application or from any record or report required under the provisions of section 512 of the act and § 514.80 or § 510.301 of this chapter of any information obtained from: ( 1 ) Investigations as to the safety, effectiveness, identity, strength, quality, or purity of the drug, made by the applicant on the drug, or
( 2 ) Investigations or experience with the product that is the subject of the application, or any related product, available to the applicant from any source if such information is pertinent to an evaluation of the safety, effectiveness, identity, strength, quality, or purity of the drug, when such omission would bias an evaluation of the safety or effectiveness of the product.
( c ) Any nonclinical laboratory study contained in the application was not conducted in compliance with the good laboratory practice regulations as set forth in part 58 of this chapter, and the application fails to include a brief statement of the reason for the noncompliance.
[40 FR 13825, Mar. 27, 1975, as amended at 49 FR 7226, Feb. 28, 1984; 50 FR 7517, Feb. 22, 1985; 68 FR 15365, Mar. 31, 2003]
Exhibit 32 (a)
 CERTIFICATION PURSUANT TO 18 U.S.C SECTION 1350, AS ADOPTED PURSUANT
TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
  (1)
    
    The Form 10-Q fully complies with the requirements of Section 13 (a) or
(15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78(d)); and(2)
    
    The information contained in the Form 10-Q fairly presents in all
material respects, the financial condition and results of operations of the
Partnership.
 Date:
8-21-08
 /s/
    
    JOHN S. WHETZELL

John S. WhetzellChief Executive Officer
 A signed original of this written statement required by Section 906 has been provided to Northland
Cable Properties Seven Limited Partnership and will be retained by Northland Cable Properties Seven
Limited Partnership and furnished to the Securities and Exchange Commission or its staff upon
request.
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Postal Service

# TIMES AND DATES: 

4 p.m., Monday, January 10, 2011; and 9 a.m., Tuesday, January 11, 2011.

# PLACE:

 Long Beach, California, at the Renaissance Hotel, 111 East Ocean Boulevard.

# STATUS:

 (Closed).

# MATTERS TO BE CONSIDERED:

### Monday, January 10, at 4 p.m. (Closed)

1. Financial Matters.

2. Pricing.

3. Strategic Issues.

4. Personnel Matters and Compensation Issues.

5. Governors' Executive Session—Discussion of prior agenda items and Board Governance.

### Tuesday, January 11, at 9 a.m. (Closed)

1. Continuation of Monday's agenda.

# CONTACT PERSON FOR MORE INFORMATION:

 Julie S. Moore, Secretary of the Board, U.S. Postal Service, 475 L'Enfant Plaza, SW., Washington, DC 20260-1000. Telephone (202) 268-4800.

Julie S. Moore,

Secretary.

[FR Doc. 2010-33358 Filed 1-3-11; 4:15 pm]

BILLING CODE 7710-12-P
§ 522.2076 Romifidine. ( a ) *Specifications.* Each milliliter of solution contains 10 milligrams (mg) romifidine hydrochloride.
( b ) *Sponsor.* See No. 000010 in § 510.600(c) of this chapter.
( c ) *Conditions of use in horses* — ( 1 ) *Amount.* 40 to 120 micrograms per kilogram of body weight (mcg/kg BW) intravenously for sedation and analgesia; 100 mcg/kg BW intravenously as a preanesthetic.
( 2 ) *Indications for use.* For use as a sedative and analgesic to facilitate handling, clinical examinations, clinical procedures, and minor surgical procedures in adult horses; and for use as a preanesthetic prior to the induction of general anesthesia in adult horses.
( 3 ) *Limitations.* Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[69 FR 47363, Aug. 5, 2004, as amended at 79 FR 16195, Mar. 25, 2014]
IIB 

118TH CONGRESS 

2D SESSION H. R. 7333 

IN THE SENATE OF THE UNITED STATES 

JULY 23, 2024 

Received; read twice and referred to the Committee on Veterans’ Affairs 

AN ACT 

To name the Department of Veterans Affairs medical center 

in West Palm Beach, Florida, as the ‘‘Thomas H. Corey 

VA Medical Center’’. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 


ssavage on LAPJG3WLY3PROD with BILLS
2 

HR 7333 RFS

1 SECTION 1. NAME OF DEPARTMENT OF VETERANS AFFAIRS 

2 MEDICAL CENTER, WEST PALM BEACH, FLOR3 IDA. 

4 The Department of Veterans Affairs medical center 

5 in West Palm Beach, Florida, shall after the date of the 

6 enactment of this Act be known and designated as the 

7 ‘‘Thomas H. Corey VA Medical Center’’. Any reference 

8 to such medical center in any law, regulation, map, docu9 ment, record, or other paper of the United States shall 

10 be considered to be a reference to the Thomas H. Corey 

11 VA Medical Center. 

Passed the House of Representatives July 22, 2024. 

Attest: KEVIN F. MCCUMBER, 

Clerk. 


ssavage on LAPJG3WLY3PROD with BILLS
CALIFORNIA AIR RESOURCES BOARD

SIP APPROVABILITY CHECKLIST--ENFORCEABILITY - PAGE 1

District: South Coast Air Quality Management District

Rule No.: 1610

Date Amended: May 9, 1997

Rule Title: Old-Vehicle Scrapping

APPLICABILITY

a. What sources are being regulated?

Stationary and indirect emission sources subiect to other specific rules and regulations, such as

Regulations XI, XIII, and XX.

See Sections (a), (c)(1), and (i) [Rule 1610 1.

b. What exemptions are provided?

See Section(s) N/A [Rule 1.

c. What is the calculation procedure for exemptions?

See Section(s) N/A [Rule 1.

d. Is the averaging time used in the rule greater than that of the applicable federal ambient

standard(s)?

No. See Section(s) N/A [Rule 1.

e. What are the units of compliance?

Total pounds of VOC, NOx, CO. or PM.

See Section (h)(1) [Rule 1610 1.

f. Is bubbling or averaging of any type allowed?

No.

g. If there is a redesignation of the AQCR to attainment, will this change the emissions limitation

in the rule?

N/A
CALIFORNIA AIR RESOURCES BOARD

SIP APPROVABILITY CHECKLIST--ENFORCEABILITY - PAGE 2

COMPLIANCE DATES

a. What is compliance date?

Rule 1610 is a voluntary rule and does not have compliance dates in itself, but does require that an

MSERC Application, a Scrapping Plan, and a Compliance Plan (for credits to be used for compliance

with Regulation XI and Regulation XIII rules) be submitted within time constraints. The compliance

dates of the applicable prerequisite Regulation XI rules for which credits are generated apply to the

submittal date of a Scrapping Plan.

See Sections (c)(3), (c~(4), (d), (e)(2), (e)(4), (h)m. (i)(5). (k)(1), & (l)(7) [Rule 1610 1.

b. What is attainment date?

Nitrogen dioxide 12/31/1995

Carbon monoxide 12/31/2000

Ozone 12/31/2010

TSP 12/31/2006

Sulfur dioxide Attained

SPECIFICITY OF CONDUCT

a. What test method is required?

Not Applicable.

b. What is the averaging time in the compliance test method?

Not Applicable.

c. Is a compliance calculation or evaluation required?

Yes. A calculation methodology is given for determining the Mobile Source Emission Reduction

Credits per scrapped vehicle.

See Section (h) [Rule 1610 1.

INCORPORATION BY REFERENCE

a. What is District authority for rulemaking?

See Board amendment Resolution.

b. What methods/rules are incorporated in the rule?

No new methods/rules were incorporated into this amendment.
CALIFORNIA AIR RESOURCES BOARD

SIP APPROVABILITY CHECKLIST--ENFORCEABILITY - PAGE 3

5. RECORDKEEPING

a. What records are required to determine compliance?

See Sections (j). (k), and (I) [Rule 1610 1.

b. What form or units must the records be kept?

See Sections (c)(4). (h), (i)(3,4), & (l)(1) [Rule 1610 1.

c. On what time basis must the records be kept?

See Sections (i)(1,2,6,7), (k)(1,5), & (I)(8) [Rule 1610 1.

d. Does the rule affirmatively require that the records be kept?

Yes. See Sections (i) and (k) [Rule 1610 1.

EXEMPTIONS

a. Are any exemptions allowed?

N/A

b. What is the criteria for application?

N/A

MALFUNCTION PROVISIONS

N/A

(ARBFORM - 6/93)
<TABLE> <S> <C>


<ARTICLE>                     5
<LEGEND>
     THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION
EXTRACTED FROM THE REGISTRANT'S BALANCE SHEET AS OF
DECEMBER 31, 1997 AND STATEMENT OF OPERATIONS FOR THE
YEAR ENDED DECEMBER 31, 1997 AND IS QUALIFIED IN ITS
ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS
</LEGEND>

       
<S>                             <C>                       <C>
<PERIOD-TYPE>                   Year                      Year
<FISCAL-YEAR-END>                          DEC-31-1997       DEC-31-1996        
<PERIOD-START>                              JAN-1-1997        JAN-1-1996
<PERIOD-END>                               DEC-31-1997       DEC-31-1996
<CASH>                                         138,469         1,516,072
<SECURITIES>                                         0                 0
<RECEIVABLES>                                3,708,498         4,377,942
<ALLOWANCES>                                    24,392            40,000
<INVENTORY>                                  3,001,519         3,275,166
<CURRENT-ASSETS>                             8,626,998        14,830,018
<PP&E>                                       2,023,294           827,802
<DEPRECIATION>                                 697,236           103,803
<TOTAL-ASSETS>                              18,934,967        22,822,892
<CURRENT-LIABILITIES>                       15,410,553        10,899,230
<BONDS>                                              0                 0
<PREFERRED-MANDATORY>                                0                 0
<PREFERRED>                                      3,520             3,785
<COMMON>                                        74,973            68,808
<OTHER-SE>                                   1,813,806         9,552,597
<TOTAL-LIABILITY-AND-EQUITY>                18,934,967        22,822,892
<SALES>                                     51,235,126        28,054,341
<TOTAL-REVENUES>                            51,235,126        28,054,341
<CGS>                                       44,667,482        23,779,175
<TOTAL-COSTS>                               44,667,482        23,779,175
<OTHER-EXPENSES>                             7,822,729         5,202,193
<LOSS-PROVISION>                                     0                 0
<INTEREST-EXPENSE>                             957,207           211,633
<INCOME-PRETAX>                             (2,812,937)       (1,165,830)
<INCOME-TAX>                                  (510,129)         (459,337)
<INCOME-CONTINUING>                         (2,302,808)         (706,493)
<DISCONTINUED>                              (7,133,152)         (378,895)
<EXTRAORDINARY>                                      0                 0
<CHANGES>                                            0                 0
<NET-INCOME>                                (9,435,960)       (1,085,388)
<EPS-PRIMARY>                                    (1.35)            (1.28)
<EPS-DILUTED>                                    (1.35)            (1.28)

        



</TABLE>
Exhibit 31.1





CERTIFICATIONS PURSUANT TO  SECTION 302 OF SARBANES-OXLEY ACT OF 2002





I, William A. Carter certify that:


|   |                                                                                 
|-- | --------------------------------------------------------------------------------
|1. | I have reviewed this annual report on Form 10-K/A of Hemispherx Biopharma, Inc.;

|   |                                                                                                                                                                                                                                                                                                           
|-- | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;




Date:  March 20, 2015





/s/ William A. Carter


William A. Carter, M.D.


Chief Executive Officer
```

[Congressional Bills 118th Congress]
[From the U.S. Government Publishing Office]
[H.R. 7423 Enrolled Bill (ENR)]

        H.R.7423

                     One Hundred Eighteenth Congress

                                 of the

                        United States of America

                          AT THE SECOND SESSION

         Begun and held at the City of Washington on Wednesday,
         the third day of January, two thousand and twenty-four

                                 An Act

 
To designate the facility of the United States Postal Service located at 
 103 Benedette Street in Rayville, Louisiana, as the ``Luke Letlow Post 
                           Office Building''.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,
SECTION 1. LUKE LETLOW POST OFFICE BUILDING.
    (a) Designation.--The facility of the United States Postal Service 
located at 103 Benedette Street in Rayville, Louisiana, shall be known 
and designated as the ``Luke Letlow Post Office Building''.
    (b) References.--Any reference in a law, map, regulation, document, 
paper, or other record of the United States to the facility referred to 
in subsection (a) shall be deemed to be a reference to the ``Luke 
Letlow Post Office Building''.

                               Speaker of the House of Representatives.

                            Vice President of the United States and    
                                               President of the Senate.
```
§ 556.445 Nicarbazin. ( a ) *Acceptable daily intake (ADI).* The ADI for total residues of nicarbazin (4,4′-dinitrocarbanilide and 2-hydroxy-4,6-dimethylpyrimidine) is 200 μg/kg of body weight per day.
( b ) *Tolerances.* The tolerance for 4,4′-dinitrocarbanilide (marker residue) is: ( 1 ) *Chickens.* Liver (target tissue): 52 ppm.
( 2 ) [Reserved]
( c ) *Related conditions of use.* See §§ 558.364 and 558.366 of this chapter.
<TABLE> <S> <C>


<ARTICLE>                                            9
<CIK>                         0000946738
<NAME>                        HARRODSBURG FIRST FINANCIAL BANCORP, INC.
<MULTIPLIER>                                   1,000
<CURRENCY>                                     U.S. Dollars
       
<S>                             <C>
<PERIOD-TYPE>                   12-MOS
<FISCAL-YEAR-END>                              SEP-30-1997
<PERIOD-START>                                 OCT-01-1996
<PERIOD-END>                                   SEP-30-1997
<EXCHANGE-RATE>                                1.000
<CASH>                                         740
<INT-BEARING-DEPOSITS>                         12,481
<FED-FUNDS-SOLD>                               0
<TRADING-ASSETS>                               0
<INVESTMENTS-HELD-FOR-SALE>                    2,717
<INVESTMENTS-CARRYING>                         11,065
<INVESTMENTS-MARKET>                           11,055
<LOANS>                                        81,569
<ALLOWANCE>                                    308
<TOTAL-ASSETS>                                 109,638
<DEPOSITS>                                     78,629
<SHORT-TERM>                                   0
<LIABILITIES-OTHER>                            1,236
<LONG-TERM>                                    0
<PREFERRED-MANDATORY>                          0
<PREFERRED>                                    0
<COMMON>                                       218
<OTHER-SE>                                     29,555
<TOTAL-LIABILITIES-AND-EQUITY>                 109,638
<INTEREST-LOAN>                                6,239
<INTEREST-INVEST>                              782
<INTEREST-OTHER>                               678
<INTEREST-TOTAL>                               7,699
<INTEREST-DEPOSIT>                             3,835
<INTEREST-EXPENSE>                             0
<INTEREST-INCOME-NET>                          3,864
<LOAN-LOSSES>                                  11
<SECURITIES-GAINS>                             0
<EXPENSE-OTHER>                                1,701
<INCOME-PRETAX>                                2,247
<INCOME-PRE-EXTRAORDINARY>                     0
<EXTRAORDINARY>                                0
<CHANGES>                                      0
<NET-INCOME>                                   1,476
<EPS-PRIMARY>                                  0.78
<EPS-DILUTED>                                  0.78
<YIELD-ACTUAL>                                 3.64
<LOANS-NON>                                    0
<LOANS-PAST>                                   520
<LOANS-TROUBLED>                               0
<LOANS-PROBLEM>                                0
<ALLOWANCE-OPEN>                               297
<CHARGE-OFFS>                                  0
<RECOVERIES>                                   0
<ALLOWANCE-CLOSE>                              308
<ALLOWANCE-DOMESTIC>                           308
<ALLOWANCE-FOREIGN>                            0
<ALLOWANCE-UNALLOCATED>                        0
        




</TABLE>